IGC Pharma (IGC) EBT (2010 - 2025)

IGC Pharma (IGC) has reported EBT for 16 consecutive years, with -$1.8 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBT fell 6.06% year-over-year to -$1.8 million in Q3 2025; TTM through Sep 2025 was -$7.6 million, a 39.18% increase from a year earlier, with the FY2026 full-year figure at -$2.4 million, up 66.27% from the prior year.
• EBT was -$1.8 million for Q3 2025 at IGC Pharma, up from -$2.8 million in the prior quarter.
• Over five years, EBT peaked at -$1.2 million in Q1 2025 and troughed at -$6.5 million in Q1 2022.
• A 5-year average of -$2.9 million and a median of -$2.4 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT sank 162.16% in 2021 and soared 67.28% in 2024, its largest moves.
• Over 5 years, EBT stood at -$2.4 million in 2021, then increased by 5.54% to -$2.2 million in 2022, then slumped by 148.51% to -$5.6 million in 2023, then soared by 67.28% to -$1.8 million in 2024, then gained by 0.44% to -$1.8 million in 2025.
• The last three EBT figures came in at -$1.8 million (Q3 2025), -$2.8 million (Q2 2025), and -$1.2 million (Q1 2025), per Business Quant data.